Slide 1: Biogen Idec Investor Presentation Spring 2009
Biogen Idec Investor Presentation Spring 2009
Slide 2: Forward Looking and Proxy Solicitation Statements
Forward Looking and Proxy Solicitation Statements This presentation includes forward-looking statements about: - our expected filings with regulatory agencies - the anticipated development and timing of programs in our clinical pipeline Each forward-looking statement is subject to risks and uncertai
Slide 3: Executive Summary
Executive Summary 13 Biogen Idec has achieved exceptional performance. Since the 2003 merger of Biogen and Idec: 17% Revenue CAGR 25% Non-GAAP diluted EPS CAGR 37% Free Cash Flow CAGR $5.1 billion returned to shareholders Biogen Idec has successfully brought the most promising drugs forward in the p
Slide 4: The Board Recognizes the Critical Importance of a Robust R&D Pipeline
The Board Recognizes the Critical Importance of a Robust R&D Pipeline 13 Biogen Idec has a proven track record of progressing life-saving drugs from the bench to the bedside Three of the most important biologic therapeutics in the history of the industry were developed by Biogen Idec - Avonex, Ritux
Slide 5: Biogen's R&D Portfolio has Grown Substantially
Biogen's R&D Portfolio has Grown Substantially 13 RMG's Decision to Criticize our R&D Productivity Fails to Consider the Potential in our Pipeline In the past 5 years, we have added 18 programs at the discovery level, 24 early stage programs and 5 late stage programs In total, we have 9 late stage p
Slide 6: R&D Productivity
R&D Productivity We have achieved approvals for new indications of marketed products, which offer attractive returns for shareholders Tysabri - Crohns Disease Rituxan - RA and RA label expansion Rituxan - CLL (Filed) We made specific and significant process improvements after the merger to ensure a
Slide 7: Biogen's BD Initiatives have been Instrumental in Augmenting our Organic Pipeline
14 Biogen's BD Initiatives have been Instrumental in Augmenting our Organic Pipeline Neurology Oncology Cardiopulmonary & Emerging Areas Immunology Daclizumab LINGO CDP323 AVONEX TYSABRI Ocrelizumab BG-12 BIIB014 Neublastin RITUXAN Ocrelizumab BG-12 FUMADERM Anti-TWEAK Elan 2000 Genentech PDL (2005)
Slide 8: Our BD Approach Always Puts the Interests of Our Shareholders First
Our BD Approach Always Puts the Interests of Our Shareholders First 13 Biogen Idec has completed over 20 Business development deals since the Merger In addition, we have completed New Venture investments in 28 companies as well as 3 incubator investments Although we are constantly looking for attrac
Slide 9: The Board is Open to Reviewing ALL Strategic Proposals from Shareholders
The Board is Open to Reviewing ALL Strategic Proposals from Shareholders 1 Most recently on CNBC Fast Money 4/8/09 The Board reviewed the proposed "Split Up" and had previously reviewed similar transactions. The Board agreed the proposed "Split Up" not in the interests of shareholders Biogen Idec's
Slide 10: Biogen Idec's Board of Directors Has a Proven Track Record
Biogen Idec's Board of Directors Has a Proven Track Record Our Board has been a consistent and watchful guardian of shareholder value Largest merger of two independent Biotechs $3B share repurchase / Dutch auction Review of all strategic alternatives (including a sale of the company) Disciplined exe
Slide 11: GAAP to non-GAAP Reconciliation
GAAP to non-GAAP Reconciliation Diluted EPS and Net Income Attributable to Biogen Idec Inc Notes: The non-GAAP financial measures presented in this table are utilized by Biogen Idec management to gain an understanding of the comparative financial performance of the Company. Our non-GAAP financial me